|
 The drugmaker's late-stage trial testing Nuplazid, stopped in
September after positive results, enrolled 392 patients aged 74.5
years on average.
Patients on the drug experienced a 65% reduction rate in relapses of
dementia-related psychotic episodes, the company said.
Chief Executive Officer Stephen Davis said Acadia planned to meet
with the U.S. regulator in the first half of next year to discuss
filing for Nuplazid's approval to include dementia-linked psychosis
on its label.
There are no FDA-approved treatments for the condition,
characterized by hallucinations and delusions.
The company estimates there are about 2.4 million dementia-related
psychosis patients in the United States, about 70% of whom have
Alzheimer's.
About 1.2 million patients have been diagnosed and are being treated
with older-generation anti-psychotics and anti-depressants, Davis
noted.
[to top of second column] |
Acadia said 4.8% of patients taking Nuplazid had serious side
effects, compared with 3.6% of patients in the placebo group.
Nuplazid was approved to treat psychosis linked to Parkinson's
disease in 2016 and Acadia recorded net product sales of $223.8
million last year.
The drug comes at a list price of $3,100 a month.
Acadia, also testing Nuplazid for use in patients with schizophrenia
and major depressive disorder, declined to comment on future
pricing.
(Reporting by Tamara Mathias, Dania Nadeem and Deena Beasley;
Editing by Shinjini Ganguli)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
